Berger Montague Investigates Potential Securities Fraud Claims Against Hims & Hers Health Inc.

Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. due to allegedly false or misleading statements made to investors. The firm is focused on the Class Period from April 29, 2025 through June 22, 2025, during which Hims & Hers shares dropped significantly after Novo Nordisk terminated their partnership.

Key Takeaways:

Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. for allegedly false or misleading statements made to investors.
The firm is focused on the Class Period from April 29, 2025 through June 22, 2025, during which shares dropped over 34% after Novo Nordisk terminated their partnership.
A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.
Investors have until August 25, 2025 to seek appointment as lead plaintiff in the class action lawsuit.
Berger Montague is a pioneer in securities class action litigation with over 50 years of experience, having represented individual and institutional investors in courts throughout the United States.
The firm has offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, and Chicago.

Statistics:

Hims & Hers shares dropped over 34% after Novo Nordisk terminated their partnership due to unauthorized marketing and sale of compounded semaglutide drugs.
The Class Period spans from April 29, 2025 through June 22, 2025.
Investors have until August 25, 2025 to seek appointment as lead plaintiff in the class action lawsuit.
Berger Montague has over 50 years of experience in securities class action litigation.

Sources:

Newsfile Corp., "Berger Montague Develops Investigation Concerning Hims & Hers Health Inc. (NYSE:HIMS) Following Announcement of Novo Nordisk's Termination of Partnership and Significant Share Price Drop", July 21, 2025